STOCK TITAN

Coherus Biosciences Inc - CHRS STOCK NEWS

Welcome to our dedicated news page for Coherus Biosciences (Ticker: CHRS), a resource for investors and traders seeking the latest updates and insights on Coherus Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Coherus Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Coherus Biosciences's position in the market.

Rhea-AI Summary
Coherus BioSciences completes acquisition of Surface Oncology, adding new immuno-oncology assets to their pipeline
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Coherus BioSciences, Inc. announced participation in investor conferences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Summary
Coherus BioSciences grants options to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Coherus BioSciences reported net revenue of $58.7 million for Q2 2023, an 81% increase from the previous quarter. CIMERLI net sales quadrupled to $26.7 million. The company launched UDENYCA autoinjector in May and YUSIMRY in July. Coherus expects continued revenue growth in the second half of the year. The planned merger with Surface Oncology is expected to advance the immuno-oncology pipeline. Coherus projects 2023 net product revenue to exceed $275 million, with at least $100 million from CIMERLI net revenue.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.74%
Tags
-
Rhea-AI Summary
Coherus BioSciences, Inc. will release its second quarter 2023 financial results on August 2, 2023, after market close. A conference call and webcast will be held to discuss the results and provide a general business update. The press release and related materials will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
conferences earnings
-
Rhea-AI Summary
Coherus BioSciences grants options to newly hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.88%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
none
-
Rhea-AI Summary
Coherus BioSciences, Inc. announces the commercial sale of YUSIMRY™ (adalimumab-aqvh) in the United States at a price of $995 per carton, representing a discount of more than 85% compared to Humira®. YUSIMRY™ is a TNF blocker indicated for the treatment of various autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.51%
Tags
none
Rhea-AI Summary
Coherus BioSciences grants options to new employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
Coherus Biosciences Inc

Nasdaq:CHRS

CHRS Rankings

CHRS Stock Data

251.35M
103.90M
1.35%
77.99%
20.8%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About CHRS

coherus biosciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. founded in 2010, coherus is a late-stage biologics platform company focused on the global biosimilar market. headquartered in the san francisco bay area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. our commercialization partnerships include global pharmaceutical companies in europe, asia and latin america. biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and exp